TLSI — TriSalus Life Sciences Balance Sheet
0.000.00%
- $149.92m
- $145.95m
- $18.51m
Annual balance sheet for TriSalus Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Cash and Equivalents | ||||
Cash and Short Term Investments | 4.49 | 30.3 | 9.41 | 11.8 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 0.617 | 1.36 | 1.56 | 3.55 |
Total Inventory | ||||
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 6.08 | 35.1 | 17.2 | 20.9 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 1.26 | 1.8 | 3.61 | 3.27 |
Net Intangible Assets | ||||
Other Long Term Assets | ||||
Total Assets | 8.13 | 37.8 | 22 | 25.7 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 54.7 | 6.37 | 32.4 | 14.7 |
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 58.3 | 6.93 | 34.3 | 51.7 |
Non Redeemable Preferred Stock | ||||
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Total Equity | -50.2 | 30.9 | -12.3 | -25.9 |
Total Liabilities & Shareholders' Equity | 8.13 | 37.8 | 22 | 25.7 |
Total Common Shares Outstanding |